Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Short Interest Update

Sangamo Therapeutics, Inc. (NASDAQ:SGMO) saw a significant decline in short interest during the month of November. As of November 15th, there was short interest totalling 13,390,000 shares, a decline of 29.5% from the October 31st total of 18,980,000 shares. Based on an average daily trading volume, of 7,230,000 shares, the short-interest ratio is presently 1.9 days.

Analyst Ratings Changes

A number of research analysts have issued reports on the company. StockNews.com upgraded Sangamo Therapeutics from a “hold” rating to a “buy” rating in a research report on Thursday. HC Wainwright reiterated a “buy” rating and issued a $10.00 target price on shares of Sangamo Therapeutics in a research report on Thursday, November 14th. Finally, Barclays boosted their price target on shares of Sangamo Therapeutics from $3.00 to $9.00 and gave the stock an “overweight” rating in a research report on Thursday, November 14th.

Sangamo Therapeutics Trading Down 1.7 %

SGMO stock traded down $0.04 during trading hours on Friday, hitting $2.26. 3,004,315 shares of the stock traded hands, compared to its average volume of 6,875,489. The stock has a 50-day simple moving average of $1.57 and a 200 day simple moving average of $0.97. The company has a market cap of $471.55 million, a P/E ratio of -3.01 and a beta of 1.10. Sangamo Therapeutics has a one year low of $0.30 and a one year high of $3.18.

Sangamo Therapeutics (NASDAQ:SGMO) last released its earnings results on Tuesday, November 12th. The biopharmaceutical company reported $0.04 EPS for the quarter, topping analysts’ consensus estimates of ($0.03) by $0.07. The business had revenue of $49.41 million for the quarter, compared to the consensus estimate of $26.55 million. Sangamo Therapeutics had a negative net margin of 257.87% and a negative return on equity of 264.16%. During the same period in the previous year, the firm earned ($0.34) EPS. Analysts forecast that Sangamo Therapeutics will post -0.52 earnings per share for the current year.

Hedge Funds Weigh In On Sangamo Therapeutics

Hedge funds have recently modified their holdings of the stock. State Board of Administration of Florida Retirement System increased its stake in Sangamo Therapeutics by 61.1% in the 1st quarter. State Board of Administration of Florida Retirement System now owns 62,345 shares of the biopharmaceutical company’s stock worth $42,000 after purchasing an additional 23,650 shares in the last quarter. Meritage Portfolio Management increased its position in shares of Sangamo Therapeutics by 8.6% in the third quarter. Meritage Portfolio Management now owns 85,000 shares of the biopharmaceutical company’s stock worth $74,000 after acquiring an additional 6,740 shares in the last quarter. XTX Topco Ltd raised its holdings in shares of Sangamo Therapeutics by 167.8% during the third quarter. XTX Topco Ltd now owns 103,716 shares of the biopharmaceutical company’s stock valued at $90,000 after acquiring an additional 64,981 shares during the period. Wealth Enhancement Advisory Services LLC lifted its position in shares of Sangamo Therapeutics by 55.4% in the 3rd quarter. Wealth Enhancement Advisory Services LLC now owns 108,945 shares of the biopharmaceutical company’s stock valued at $94,000 after acquiring an additional 38,850 shares in the last quarter. Finally, Virtu Financial LLC acquired a new position in Sangamo Therapeutics in the 3rd quarter worth approximately $150,000. 56.93% of the stock is currently owned by institutional investors and hedge funds.

About Sangamo Therapeutics

Sangamo Therapeutics, Inc, a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease.